RNA interference (RNAi) is a scientific breakthrough that, thanks to the determination of both academic and industry researchers, is empowering desperately needed progress against rare diseases. Global health threats like COVID-19 have further demonstrated the significance of this innovative platform.
Join Research!America and partners for a virtual panel discussion focusing on the influence of RNAi technology on medical progress. Participants will explore the impact of RNAi technology in addressing unmet medical needs and demonstrate the symbiotic roles of the public and private sectors.
Elias A. Zerhouni, MD, professor emeritus, Johns Hopkins University, former director, National Institutes of Health, 2002-2008
Isabelle Lousada, president & CEO, Amyloidosis Research Consortium
Phillip A. Sharp, PhD, institute professor, and professor of Biology, MIT; member, Koch Institute for Integrative Cancer Research at MIT; 1993 Nobel Prize in Physiology or Medicine
Akshay Vaishnaw, MD, PhD, president, Research & Development, Alnylam Pharmaceuticals
Brian Zambrowicz, PhD, senior vice president, Functional Genomics and Chief VelociGene® Operations, Regeneron Pharmaceuticals